Literature DB >> 23052241

[Vestibular schwannoma. Part 2: therapy, prognosis, and rehabilitation].

W Maier1, F Hassepaß, A Aschendorff, R Laszig.   

Abstract

During the past few decades, therapeutic options in vestibular schwannoma have become more versatile. The former dominant surgical strategies are complemented by radiotherapeutic procedures and the so-called wait-and-scan option. Therefore, the decision to proceed has become more difficult and individual solutions should be found on an interdisciplinary basis. In particular, patients suffering from neurofibromatosis type 2 should be discussed in an experienced center. Furthermore, rehabilitation of auditory, vestibular, motoric, and neurologic functions requires extended experience in this complex disease.

Entities:  

Mesh:

Year:  2012        PMID: 23052241     DOI: 10.1007/s00106-012-2534-x

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  29 in total

1.  Small acoustic neuromas: surgical outcomes versus observation or radiation.

Authors:  Ted A Meyer; Paul A Canty; Eric P Wilkinson; Marlan R Hansen; Jay T Rubinstein; Bruce J Gantz
Journal:  Otol Neurotol       Date:  2006-04       Impact factor: 2.311

2.  Efficacy of corticosteroids in hearing preservation after radiosurgery for vestibular schwannoma: a prospective study.

Authors:  Jin Wook Kim; Dong Gyu Kim; Sun Ha Paek; Hyun-Tai Chung; Yong Hwy Kim; Jung Ho Han; Chul-Kee Park; Hee-Won Jung
Journal:  Stereotact Funct Neurosurg       Date:  2010-12-15       Impact factor: 1.875

3.  Endoscopy of the internal auditory canal during hearing conservation acoustic tumor surgery.

Authors:  K X McKennan
Journal:  Am J Otol       Date:  1993-05

4.  Central electrical stimulation of the auditory pathway in neurofibromatosis type 2.

Authors:  R Laszig; N Marangos; W P Sollmann; R T Ramsden
Journal:  Ear Nose Throat J       Date:  1999-02       Impact factor: 1.697

5.  [Stereotactic radiosurgery and fractionated stereotactic radiotherapy of acoustic neuromas].

Authors:  F Unger; K Dominikus; K Haselsberger
Journal:  HNO       Date:  2011-01       Impact factor: 1.284

6.  [Modification of the retrolabyrinthine approach with hearing preservation in CPA tumors].

Authors:  J Schipper; P Lohnstein; W Stummer; F Knapp; B Turowski; T Klenzner
Journal:  Laryngorhinootologie       Date:  2009-08-28       Impact factor: 1.057

7.  Management of acoustic neuromas in patients 65 years or older.

Authors:  Pamela C Roehm; Bruce J Gantz
Journal:  Otol Neurotol       Date:  2007-08       Impact factor: 2.311

8.  Middle fossa versus retrosigmoid-transmeatal approach in vestibular schwannoma surgery: a prospective study.

Authors:  Vittorio Colletti; Francesco Fiorino
Journal:  Otol Neurotol       Date:  2003-11       Impact factor: 2.311

9.  Long-term outcome of stereotactic radiosurgery (SRS) in patients with acoustic neuromas.

Authors:  Stephanie E Combs; Christoph Thilmann; Jürgen Debus; Daniela Schulz-Ertner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-02-07       Impact factor: 7.038

Review 10.  Guiding patients through the choices for treating vestibular schwannomas: balancing options and ensuring informed consent.

Authors:  Douglas D Backous; Huong T Pham
Journal:  Otolaryngol Clin North Am       Date:  2007-06       Impact factor: 3.346

View more
  2 in total

1.  Stereotactic radiotherapy of vestibular schwannoma : Hearing preservation, vestibular function, and local control following primary and salvage radiotherapy.

Authors:  Florian Putz; Jan Müller; Caterina Wimmer; Nicole Goerig; Stefan Knippen; Heinrich Iro; Philipp Grundtner; Ilker Eyüpoglu; Karl Rössler; Sabine Semrau; Rainer Fietkau; Sebastian Lettmaier
Journal:  Strahlenther Onkol       Date:  2016-12-07       Impact factor: 3.621

2.  Cochlear implantation for hearing rehabilitation in single-sided deafness after translabyrinthine vestibular schwannoma surgery.

Authors:  Frederike Hassepass; Susan Arndt; Antje Aschendorff; Roland Laszig; Thomas Wesarg
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-10-23       Impact factor: 2.503

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.